For immediate release July 21, 2015
Contact: Stuart Moss
Nathan Kline Institute
Study Reveals Specific Protein As Missing Link Responsible for Earliest Known Change in Alzheimer’s Disease Pathology
July 21, 2015
Study Reveals Specific Protein As Missing Link Responsible for Earliest Known Change in Alzheimer´s Disease Pathology
Findings May Influence Strategies for Treatment
NEW YORK, July 21, 2015 -- A recent study conducted at Nathan S. Kline Institute for Psychiatric Research (NKI) and NYU Langone Medical Center implicates a new culprit in Alzheimer´s disease development. The research reveals that ßCTF -- the precursor of the amyloid beta (Aß) peptide -- acts at the earliest stage of Alzheimer´s to initiate a range of abnormalities leading to the loss of groups of neurons critical for memory formation. Results from the study are to be published online July 21, 2015 in the journal Molecular Psychiatry, and the article has been selected for an issue cover.
The recent study findings involving ßCTF have significant implications for treatment strategies and furthering the course of Alzheimer´s drug development. Presently, the most common strategy for treating Alzheimer´s disease is targeting the amyloid ß peptide, which has had modest success in clinical trials. Findings from this research suggest that drugs that may reduce ßCTF levels as well as beta-amyloid, such as the class of BACE1 inhibitors currently under development, may help slow or stop the progression of Alzheimer´s disease.
ßCTF is formed during endocytosis, the process by which cells absorb nutrients and sample various materials from the outside environment. It has been known for some time that abnormalities of endocytosis develop very early in Alzheimer´s disease, well before clinical symptoms, and that variant forms of genes controlling endocytosis are frequently implicated as risk factors promoting Alzheimer´s. Endosomes -- the membranous vesicles mediating endocytosis -- start to swell abnormally in some neurons beginning even in infancy in Down syndrome - a developmental disability that almost invariably leads to early-onset AD. Research indicates that more than 75 percent of those with Down´s, aged 65 and older, have Alzheimer´s disease.
The NYU Langone - NKI research team led by Ralph Nixon, MD, PhD, professor in the departments of psychiatry and cell biology at NYU Langone School of Medicine and director of the Center for Dementia Research at the Nathan S. Kline Institute for Psychiatric Research found that, in Alzheimer´s and Down Syndrome, ßCTF forms more rapidly on endosomes triggering a molecular pathway leading to loss of neurons involved with memory. The researchers discovered APPL1, a protein unrelated to amyloid precursor protein (APP) despite its similar acronym, directly links ßCTF to a second protein, rab5, known to activate the molecular chain of events leading to neurodegeneration. Lowering APPL1 levels in cells of individuals with Down syndrome abolished the abnormal endocytosis, indicating the vital role of APPL1 in this molecular cascade. The identification of APPL1 as the missing link in a well-described chain of events associated with very early Alzheimer pathology implies a direct contribution of ßCTF to Alzheimer´s disease development. Notably, a recently discovered APP mutation that uniquely lowers, rather than raising, risk for Alzheimer´s is believed to act by slowing the formation of ßCTF.
While the current findings do not place any more or less importance to Aß as a culprit and a target for Alzheimer´s therapy, they now underscore the importance of ßCTF as a key contributor to disease development. "It will be important to consider the role of ßCTF in the design of future therapies for Alzheimer´s disease and in the interpretation of current clinical trials of BACE1 inhibitors. BACE1 inhibitor trials have been considered a test of the Aß/amyloid hypothesis but the primary action of these inhibitors is actually to block formation of ßCTF, the precursor of Aß," said Ralph A. Nixon, MD, PhD.
These findings are a result of an eight year investigative track funded by the National Institute on Aging. In addition to Ralph Nixon, Seonil Kim, PhD played the major role in the study, in collaboration with other NKI and NYU researchers Yutaka Sato PhD, Panaiyur S. Mohan, PhD, Corrinne Peterhoff, Anna Pensalfini, MS, PhD, Andrew Rigoglioso, and Ying Jiang, PhD.
The Center for Dementia Research (CDR) is a consortium of independent laboratories and research programs at the Nathan S. Kline Institute for Psychiatric Research (NKI) dedicated to studies on the pathogenesis, diagnosis, and treatment of Alzheimer´s disease (AD) and other major neurodegenerative diseases. The CDR comprises over 15 principal investigators and 60 staff. Affiliated with NYU School of Medicine, NKI is one of two major institutes for psychiatric research supported in part by the New York State Office of Mental Health. A broad range of studies is conducted at NKI, including basic, translational and clinical research with a focus on improving care for those suffering from complex, psychobiologically-based, severely disabling mental disorders.
Read the full paper here.
## ## ##
Located on the grounds of Rockland Psychiatric Center, The Nathan Kline Institute for Psychiatric Research is a facility of the New York State Office of Mental Health that is nationally and internationally renowned for its pioneering contributions to psychiatric research.
Back to main News page.